Artesunate inhibits osteoclastogenesis through the miR-503/RANK axis

Area of Science:

• Biochemistry
• Molecular Biology
• Pharmacology

Background:

• Osteoporosis is a metabolic bone disease characterized by reduced bone density and strength, often driven by increased osteoclast activity.
• Targeting osteoclast activation is a primary strategy for reversing bone destruction and managing osteoporosis-related pain.

Purpose of the Study:

• To investigate the effects of artesunate on osteoclastogenesis and its underlying molecular mechanisms.
• To determine if artesunate modulates the miR-503/RANK axis and associated signaling pathways (MAPK, AKT) in osteoclast differentiation.

Main Methods:

• Cell viability was assessed using MTT assays on RAW264.7 cells treated with artesunate.
• Osteoclast activity was evaluated through TRACP staining and pit formation assays.
• Gene and protein expression levels of osteoclastogenesis markers (NFATc1, TRAP, cathepsin k, RANK) and signaling pathway components (p-Akt, p-p38, p-ERK) were analyzed via qRT-PCR and Western blotting.
• Direct targeting of RANK by miR-503 was confirmed using a luciferase reporter assay.

Main Results:

• Artesunate treatment significantly inhibited TRACP-positive cell formation and osteoclast pit-forming activity.
• Artesunate treatment led to increased expression of miR-503.
• The compound suppressed the expression of osteoclastogenesis-related genes and RANKL-induced activation of the MAPK and AKT pathways.
• miR-503 was found to directly target and inhibit RANK expression during osteoclast differentiation.

Conclusions:

• Artesunate effectively inhibits osteoclastogenesis and osteoclast function in vitro.
• The therapeutic effect of artesunate involves the regulation of the miR-503/RANK axis and the suppression of MAPK and AKT signaling pathways.
• These findings suggest artesunate as a potential therapeutic agent for osteoporosis by modulating key molecular targets involved in bone resorption.